<DOC>
	<DOCNO>NCT01794572</DOCNO>
	<brief_summary>In Multiple Myeloma , adult hematological malignancy , mainly locate Bone Marrow ( BM ) , dramatic recent progress observe , thanks new agent ( proteasome inhibitor IMIDs ) . However , time first relapse , high-dose therapy follow Stem Cell Rescue ( SCR ) frequently mandatory consolidation minimal residual disease , healthy patient 65 yo , combine Melphalan ( MPH ) and/or Total Body Irradiation . Modern irradiation modality available use HI-ART Tomotherapy system realize Total Bone Marrow Irradiation ( TBMI ) , order limit dose administer Organ Risk ( lung , oral cavity ) focus efficacy BM . In phase-1 study , condition regimen SCR combine fix high-dose MPH ( 140 mg/m² ) dose escalate TBMI , define Maximal Tolerated Dose ( MTD ) Dose Limiting Toxicities ( DLT ) . An extended cohort phase-2 setting .</brief_summary>
	<brief_title>Phase 1-2 Study Total Bone Marrow Irradiation With Helicoidal Tomotherapy 1st Myeloma Relapse</brief_title>
	<detailed_description>Experimental : Total Bone Marrow Irradiation ( TBMI ) deliver Tomotherapy HI-ART machine , 2 fraction per day 4 consecutive day -6 -3 . The escalated dose level determine accord `` 3x3 '' modify Fibonacci method five dose level explore . The dos per fraction : 1gy , 1.25gy , 1.5gy , 1.75gy 2gy , consequently cumulative TBMI dos : 8gy , 10gy , 12gy , 14gy 16gy . Drug : Melphalan infuse intravenously 30 minute day -2 IV anti-emetics . Autologous Peripheral Stem Cell Rescue : re-infused central line day `` 0 '' adequate premedication . Despite recent find new drug ( proteasome inhibitor IMIDs ) , Multiple Myeloma still remain uncurable , especially first relapse , even respond disease conventional chemotherapy . In healthy young patient ( &lt; 65 yo ) , peripheral stem cell collection available , high-dose therapy often propose consolidation complete good partial remission : conditioning regimen usually include high dose alkylating agent ( mostly Melphalan ) and/or Total Body Irradiation . The new Tomotherapy HI-ART technology allow irradiate 1.6m length field bone marrow sit together optimal respect Organ Risk ( lung , oral cavity , heart , liver , kidneys… ) . The propose phase-1 study explore safety efficacy escalate dose Total Bone-Marrow Irradiation combination fix dose Melphalan ( 140mg/m² ) , follow autologous SCR . To determine MTD main objective study , toxicity profile ( DLTs ) RP2D extend cohort MTD dose .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Multiple Myeloma first relapse . In Complete good partial remission Available Collected Autologous Peripheral Stem cell : 2.5x106 CD34+/Kg Uncontrolled visceral disease : kidney , heart , lung , diabetes mellitus Previous Total body irradiation Any previous radiation dose spinal cord could reach 45gy equivalent , include propose TBMI Amyloidosis Brain localization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapse</keyword>
	<keyword>Complete Remission</keyword>
	<keyword>Very Good Partial Remission</keyword>
</DOC>